TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 11973443
Drug: Transdermal E2/LNG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Transdermal E2/LNG and E2
Study: 11973443
Drug: Transdermal E2/LNG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Transdermal E2/LNG
Study: 2478428
Drug: Adjuvant chemotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adjuvant chemotherapy with cisplatin, vinblastine, and bleomycin (PVB)
Study: 2478428
Drug: No adjuvant
Approvals — FDA: no, EMA: no, PMDA: no
Description: No adjuvant treatment (refused adjuvant therapy)
Study: 2478428
Drug: Low-risk group
Normalized name: low-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low-risk group (no specific treatment mentioned)
Study: 2478428
Drug: High-risk group
Normalized name: high-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-risk group (no specific treatment mentioned)
Study: 30229847
Drug: Hydromorphone intravenous
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hydromorphone intravenous analgesia
Study: 30229847
Drug: Morphine intravenous
Approvals — FDA: no, EMA: no, PMDA: no
Description: Morphine intravenous analgesia
Study: 16086617
Drug: Risperidone (1-6
Approvals — FDA: no, EMA: no, PMDA: no
Description: Risperidone (1-6 mg/day)
Study: 11099601
Drug: Methacholine inhalation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Methacholine inhalation challenge (group N-A)
Study: 11099601
Drug: Methacholine inhalation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Methacholine inhalation challenge (group N-N)
Study: 11099601
Drug: Methacholine inhalation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Methacholine inhalation challenge (group A-A)
Study: 27221806
Drug: Dapagliflozin added
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dapagliflozin added to metformin
Study: 27221806
Drug: Dipeptidyl-peptidase-4 inhibitor
Normalized name: Fibrinolysis inhibitor
DrugBank: Aprotinin (DB06692)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Dipeptidyl-peptidase-4 inhibitor (DPP-4i)
Study: 20812339
Drug: Prednisolone (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prednisolone (20 mg/day for 14 days)
Study: 10617012
Drug: EACA (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: EACA (5 g bolus, 2 g/h infusion, 2.5 g in priming)
Study: 10617012
Drug: TA (1
Normalized name: {56 (elexacaftor 100 MG / ivacaftor 75 MG / tezacaftor 50 MG Oral Tablet) / 28 (ivacaftor 150 MG Oral Tablet) } Pack [Trikafta (100 MG / 50 MG / 75 MG; 150 MG)]
Approvals — FDA: no, EMA: no, PMDA: no
Description: TA (1 g bolus, 400 mg/h infusion, 500 mg in priming)
Study: 10617012
Drug: AP (280
Approvals — FDA: no, EMA: no, PMDA: no
Description: AP (280 mg bolus, 70 mg/h infusion, 280 mg in priming)
Study: 1985413
Drug: Vitamin E
Normalized name: Vitamin E
DrugBank: Vitamin E (DB00163)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Vitamin E supplementation (20 mg/kg im soon after birth, and at 24 and 48 hours)
Study: 1985413
Drug: Vitamin E
Normalized name: Vitamin E
DrugBank: Vitamin E (DB00163)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Vitamin E supplementation (single dose of 20 mg/kg)
Study: 6189581
Drug: Radiation therapy
Normalized name: Sensitizers used in photodynamic/radiation therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Radiation therapy for cerebral metastases
Study: 6189581
Drug: Radiation therapy
Normalized name: Sensitizers used in photodynamic/radiation therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Radiation therapy for headaches
Study: 6189581
Drug: Radiation therapy
Normalized name: Sensitizers used in photodynamic/radiation therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Radiation therapy for convulsions
Study: 6189581
Drug: Radiation therapy
Normalized name: Sensitizers used in photodynamic/radiation therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Radiation therapy for motor loss
Study: 6189581
Drug: Radiation therapy
Normalized name: Sensitizers used in photodynamic/radiation therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Radiation therapy for bone metastases in prostatic carcinoma
Study: 6189581
Drug: Radiation therapy
Normalized name: Sensitizers used in photodynamic/radiation therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Radiation therapy for bone metastases in renal primaries
Study: 6189581
Drug: Radiation therapy
Normalized name: Sensitizers used in photodynamic/radiation therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Radiation therapy for pain relief at eight weeks
Study: 6189581
Drug: Radiation therapy
Normalized name: Sensitizers used in photodynamic/radiation therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Radiation therapy for total group of patients
Study: 21339433
Drug: Casopitant plus
Normalized name: casopitant
DrugBank: Casopitant (DB06634)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Casopitant plus ondansetron (oral casopitant 50 mg + intravenous ondansetron 4 mg)
Study: 21339433
Drug: Ondansetron only
Normalized name: Ondansetron only product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ondansetron only (intravenous ondansetron 4 mg)
Study: 19900234
Drug: Amitriptyline 50
Normalized name: amitriptyline 50 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amitriptyline 50 mg at night
Study: 15354947
Drug: Pulse intravenous
Normalized name: dulse extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pulse intravenous cyclophosphamide
Study: 17066740
Drug: Daily oral
Normalized name: GEMTESA 75 MG Once-Daily Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily oral cyclophosphamide
Study: 10651841
Drug: rhEPO plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: rhEPO plus intravenous iron sucrose (group 1)
Study: 10651841
Drug: rhEPO placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: rhEPO placebo plus intravenous iron sucrose (group 2)
Study: 10651841
Drug: oral iron
Approvals — FDA: no, EMA: no, PMDA: no
Description: oral iron alone (group 3)
Study: 9580102
Drug: Isoxsuprine (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Isoxsuprine (50 mg in 250 ml of DW5%)
Study: 8160562
Drug: Cetirizine 20
Normalized name: cetirizine 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cetirizine 20 mg (10 mg twice a day)
Study: 3511182
Drug: Urabe Am
Normalized name: Urate oxidase
DrugBank: Rasburicase (DB00049)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Urabe Am 9‐Schwarz vaccine
Study: 3511182
Drug: Jeryl Lynn‐Moraten
Approvals — FDA: no, EMA: no, PMDA: no
Description: Jeryl Lynn‐Moraten vaccine
Study: 27470259
Drug: Supportive-expressive group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Supportive-expressive group (SEG) therapy
Study: 15188939
Drug: Hypertensive patients
Normalized name: patent blue violet
DrugBank: Patent Blue (DB13967)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hypertensive patients receiving contemporary medical therapy
Study: 15188939
Drug: Non-hypertensive patients
Normalized name: Tavist Non-Sedating
Approvals — FDA: no, EMA: no, PMDA: no
Description: Non-hypertensive patients receiving contemporary medical therapy
Study: 12363115
Drug: Aripiprazole 15
Normalized name: aripiprazole 15 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aripiprazole 15 mg/day and Haloperidol 10 mg/day
Study: 7947240
Drug: rHuEPO (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: rHuEPO (200 units/kg intravenous bolus daily) for 28 days or until Hct of 35% reached
Study: 3332575
Drug: Nifedipine GITS,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nifedipine GITS, 30 or 60 mg daily
Study: 3332575
Drug: Hydrochlorothiazide, 25
Normalized name: HydroCHLOROthiazide, 25 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hydrochlorothiazide, 25 or 50 mg daily
Study: 11739337
Drug: Pharmaceutical industry
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Pharmaceutical industry support
Study: 24697872
Drug: Oral terbinafine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral terbinafine for 2 weeks and topical terbinafine and 10% urea ointment for 4 weeks
Study: 24697872
Drug: Topical terbinafine
Normalized name: terbinafine Topical Solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical terbinafine and 10% urea ointment for 12 weeks
Study: 18271228
Drug: Acupuncture treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acupuncture treatment (needling method at Baihui (GV 20), Shenting (GV 24), Shenmen (HT 7))
Study: 10102158
Drug: High-dose intravenous
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose intravenous immunoglobulin (HDIVIG) therapy (1 g kg(‐1), over 4 h) with phototherapy
Study: 2197716
Drug: multimodal hospital
Approvals — FDA: no, EMA: no, PMDA: no
Description: multimodal hospital treatment without IFI
Study: 2197716
Drug: multimodal hospital
Approvals — FDA: no, EMA: no, PMDA: no
Description: multimodal hospital treatment with IFI
Study: 21504
Drug: HC 20‐511
Approvals — FDA: no, EMA: no, PMDA: no
Description: HC 20‐511 4 mg daily
Study: 21504
Drug: HC 20‐511
Approvals — FDA: no, EMA: no, PMDA: no
Description: HC 20‐511 2 mg daily
Study: 21504
Drug: Cyproheptadine (Periactin)
Normalized name: cyproheptadine hydrochloride Oral Solution [Periactin]
DrugBank: Cyproheptadine (DB00434)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Cyproheptadine (Periactin) 8 mg daily
Study: 24734908
Drug: Setipiprant 2000
Normalized name: Setipiprant
DrugBank: Setipiprant (DB12562)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Setipiprant 2000 mg single dose
Study: 24734908
Drug: Setipiprant 500
Normalized name: Setipiprant
DrugBank: Setipiprant (DB12562)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Setipiprant 500 mg b.i.d. for 5.5 days
Study: 24734908
Drug: Setipiprant 1000
Normalized name: Setipiprant
DrugBank: Setipiprant (DB12562)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Setipiprant 1000 mg b.i.d. for 5.5 days
Study: 24734908
Drug: Setipiprant (single
Approvals — FDA: no, EMA: no, PMDA: no
Description: Setipiprant (single and multiple doses)
Study: 24734908
Drug: Urinary excretion
Approvals — FDA: no, EMA: no, PMDA: no
Description: Urinary excretion of unchanged setipiprant
Study: 15001199
Drug: Perindopril 2
Normalized name: perindopril 2 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Perindopril 2 mg plus Indapamide 0.625 mg
Study: 15187802
Drug: Pemoline (75
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pemoline (75 to 112.5 mg, titrated over 4 weeks to a single morning dose for 12 weeks)
Study: 11328223
Drug: 200 mg
Normalized name: RNA 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 200 mg mifepristone followed by gemeprost 1 mg vaginally
Study: 11328223
Drug: 600 mg
Normalized name: mesna 600 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 600 mg mifepristone followed by gemeprost 1 mg vaginally
Study: 7955441
Drug: recombinant human
Normalized name: Recombinant human TNF
DrugBank: Etanercept (DB00005)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: recombinant human growth hormone (rhGH) replacement therapy (0.018 U/kg/day for 1 month followed by 0.036 U/kg/day for 1 month)
Study: 25818264
Drug: Intralesional injection
Normalized name: DEXAMETHASONE SODIUM PHOSPHATE 4 mg in 1 mL INTRALESIONAL INJECTION
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intralesional injection of collagenase Clostridium histolyticum (CCH) 0.58 mg
Study: 24340995
Drug: HyperHAES solution
Normalized name: Hyperhep B Injectable Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: HyperHAES solution used during prolonged veno-venous haemofiltration
Study: 12955428
Drug: Subcutaneous octreotide
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subcutaneous octreotide administered 1 hour before stenting and every 8 hours for 3 weeks
Study: 12955428
Drug: Placebo administered
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo administered 1 hour before stenting and every 8 hours for 3 weeks
Study: 12955428
Drug: Subcutaneous octreotide
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subcutaneous octreotide
Study: 29973117
Drug: Education with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Education with fluorescent gel
Study: 28323043
Drug: High dose
Normalized name: INFLUENZA VACCINE HIGH DOSE 0.5ML SYR
Approvals — FDA: no, EMA: no, PMDA: no
Description: High dose vitamin D3 (20,000 IU twice a week)
Study: 28323043
Drug: Standard dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard dose (placebo)
Study: 27411750
Drug: Complementary and
Normalized name: cytarabine and daunorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Complementary and alternative medicine (CAM) use at baseline
Study: 27411750
Drug: Complementary and
Normalized name: cytarabine and daunorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Complementary and alternative medicine (CAM) use at 52 weeks
Study: 23107894
Drug: Carvedilol (C,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Carvedilol (C, 20 then 40 mg/day)
Study: 23107894
Drug: Valsartan (V,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Valsartan (V, 160 then 320 mg/day)
Study: 7398983
Drug: Local application
Normalized name: docusate calcium / phenolphthalein Oral Capsule [Docal]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Local application of hair lotions with 17 alpha-estradiol (0.025%)
Study: 7398983
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (hair lotions without 17 alpha-estradiol)
Study: 26463318
Drug: ODM-201 (600
Approvals — FDA: no, EMA: no, PMDA: no
Description: ODM-201 (600 mg dose in capsules and tablets)
Study: 26463318
Drug: ODM-201 (600
Approvals — FDA: no, EMA: no, PMDA: no
Description: ODM-201 (600 mg twice daily in capsules)
Study: 23135530
Drug: Topical cyclosporine
Normalized name: Cyclosporine
DrugBank: Cyclosporine (DB00091)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical cyclosporine 0.05% (group A)
Study: 20813689
Drug: Oxymatrine (150
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oxymatrine (150 mg daily, intravenously)
Study: 20813689
Drug: Gluthion (1.2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gluthion (1.2 g daily, intravenously)
Study: 8201768
Drug: SY5555 dry
Approvals — FDA: no, EMA: no, PMDA: no
Description: SY5555 dry syrup at 3 mg/kg
Study: 8201768
Drug: SY5555 dry
Approvals — FDA: no, EMA: no, PMDA: no
Description: SY5555 dry syrup at 5 mg/kg
Study: 8201768
Drug: SY5555 dry
Approvals — FDA: no, EMA: no, PMDA: no
Description: SY5555 dry syrup at 10 mg/kg
Study: 8201768
Drug: SY5555 dry
Approvals — FDA: no, EMA: no, PMDA: no
Description: SY5555 dry syrup at 15 mg/kg
Study: 8201768
Drug: SY5555 dry
Approvals — FDA: no, EMA: no, PMDA: no
Description: SY5555 dry syrup (overall clinical efficacy)
Study: 8201768
Drug: SY5555 dry
Approvals — FDA: no, EMA: no, PMDA: no
Description: SY5555 dry syrup at daily doses of 12 - < 18 mg/kg
Study: 8201768
Drug: SY5555 dry
Approvals — FDA: no, EMA: no, PMDA: no
Description: SY5555 dry syrup at daily doses of 18 - < 27 mg/kg
Study: 8201768
Drug: SY5555 dry
Approvals — FDA: no, EMA: no, PMDA: no
Description: SY5555 dry syrup at daily doses of 27 - < 33 mg/kg
Study: 8201768
Drug: SY5555 dry
Approvals — FDA: no, EMA: no, PMDA: no
Description: SY5555 dry syrup (bacteriological eradication)
Study: 2883952
Drug: Nasal spray
Normalized name: Nasal Spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nasal spray of LHRH, 0.4 mg thrice daily during 28 consecutive days
Study: 2883952
Drug: Nasal spray
Normalized name: Nasal Spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nasal spray of LHRH, 0.4 mg twice daily on alternate days for 1 month
Study: 2883952
Drug: Nasal spray
Normalized name: Nasal Spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nasal spray of LHRH, 0.4 mg twice daily on alternate days for 3 months
Study: 29731444
Drug: CSP 400mg
Normalized name: INV-CSP #2002 METFORMIN OR PLACEBO
Approvals — FDA: no, EMA: no, PMDA: no
Description: CSP 400mg + Metformin 600mg (DT1)
Study: 29731444
Drug: Metformin 600mg
DrugBank: Metformin (DB00331)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Metformin 600mg (PC)
Study: 26434382
Drug: Lidocaine gel
Normalized name: LIDOCAINE 4 g in 100 g EXTRACORPOREAL PATCH [Arthcal 4% Lidocaine Gel Patches]
DrugBank: Lidocaine (DB00281)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Lidocaine gel group (3 mL 2% lidocaine gel applied to the cervix and intrauterine infusion of 5 mL normal saline)
Study: 26434382
Drug: Lidocaine infusion
Normalized name: Lidocaine
DrugBank: Lidocaine (DB00281)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Lidocaine infusion group (3 mL gel lubricant applied to the cervix and intrauterine infusion of 5 mL 2% lidocaine)
Study: 26434382
Drug: Placebo group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo group (3 mL gel lubricant applied to the cervix and intrauterine infusion of 5 mL normal saline)
Study: 25034216
Drug: Simultaneous initiation
Normalized name: brigatinib
DrugBank: Brigatinib (DB12267)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Simultaneous initiation of insulin pump therapy (Medtronic Veo©) and continuous glucose monitoring (CGM) (Enlite©)
Study: 25034216
Drug: Standard pump
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard pump therapy with delayed CGM introduction
Study: 17118998
Drug: 0.1 mg
Normalized name: biotin 0.1 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.1 mg TAK-677 BID (n = 21)
Study: 17118998
Drug: 0.5 mg
Normalized name: biotin 0.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.5 mg TAK-677 BID (n = 22)
Study: 8081529
Drug: Sustained-release magnesium
Normalized name: Sustained Release Buccal Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sustained-release magnesium chloride (Slo-Mag), 384 mg/d
Study: 4552591
Drug: Active drug
Normalized name: Capillary active drug
Approvals — FDA: no, EMA: no, PMDA: no
Description: Active drug (bethanidine, debrisoquine, guanethidine)
Study: 28968163
Drug: Abemaciclib plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Abemaciclib plus a nonsteroidal aromatase inhibitor (150 mg twice daily continuous schedule)
Study: 28968163
Drug: Abemaciclib plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Abemaciclib plus a nonsteroidal aromatase inhibitor
Study: 22975340
Drug: Dengue vaccine
Normalized name: Dengue vaccine
DrugBank: Dengue tetravalent vaccine, live (DB14764)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dengue vaccine (3 injections at months 0, 6, and 12)
Study: 22975340
Drug: Control (rabies
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control (rabies vaccine or placebo)
Study: 10449888
Drug: valsartan (80
Approvals — FDA: no, EMA: no, PMDA: no
Description: valsartan (80 mg/160 mg q.d.)
Study: 10449888
Drug: atenolol (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: atenolol (50 mg/100 mg q.d.)
Study: 577626
Drug: Streptokinase ('Kabikinase')
Normalized name: streptokinase Injectable Solution [Kabikinase]
DrugBank: Streptokinase (DB00086)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Streptokinase ('Kabikinase') followed by oral anticoagulant therapy
Study: 577626
Drug: Ancrod ('Arvin')
Normalized name: ancrod
DrugBank: Ancrod (DB05099)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ancrod ('Arvin') for 6 days followed by oral anticoagulant therapy
Study: 577626
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (oral anticoagulant therapy only)
Study: 577626
Drug: Streptokinase and
Approvals — FDA: no, EMA: no, PMDA: no
Description: Streptokinase and ancrod treatments
Study: 30956267
Drug: Bisoprolol 5
Normalized name: bisoprolol 5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bisoprolol 5 mg/day
Study: 30956267
Drug: Carvedilol 20
Normalized name: Carvedilol 20mg Oral capsule, extended release
Approvals — FDA: no, EMA: no, PMDA: no
Description: Carvedilol 20 mg/day
Study: 28253389
Drug: Drug-induced sleep
Approvals — FDA: no, EMA: no, PMDA: no
Description: Drug-induced sleep endoscopy with polygraphic monitoring (DISE-PG)
Study: 24010992
Drug: 0.3 mg
Normalized name: biotin 0.3 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.3 mg sublingual nitroglycerin tablet
Study: 24010992
Drug: 0.6 mg
Normalized name: thymol 0.6 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.6 mg sublingual nitroglycerin tablet
Study: 24010992
Drug: 20 mg
Normalized name: urea 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 mg tablet of isosorbide mononitrate
Study: 24010992
Drug: 160 mg
Normalized name: nadolol 160 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 160 mg nitroglycerin transdermal patch (used for 8 h)
Study: 24010992
Drug: 15 mg
Normalized name: papain 15 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 15 mg of nitroglycerin ointment
Study: 21293309
Drug: Atomoxetine (ATX)
DrugBank: Atomoxetine (DB00289)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Atomoxetine (ATX) 80 mg/day
Study: 19298581
Drug: Esomeprazole 20
Normalized name: esomeprazole 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Esomeprazole 20 mg once daily for 6 months
Study: 19298581
Drug: Pantoprazole 20
Normalized name: pantoprazole 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pantoprazole 20 mg once daily for 6 months
Study: 15134122
Drug: HIV prevention
Approvals — FDA: no, EMA: no, PMDA: no
Description: HIV prevention messages disseminated through community popular opinion leaders (CPOLs); specific details on dosage and duration not available.
Study: 11483788
Drug: Daily antiinflammatory
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily antiinflammatory medications (mostly cromolyn sodium)
Study: 11483788
Drug: Daily antiinflammatory
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily antiinflammatory medications
Study: 9891542
Drug: Multi-drug regimens
Normalized name: Anacin Aspirin Regimen Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Multi-drug regimens
Study: 9891542
Drug: Single agent
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single agent treatment (usually BCNU)
Study: 1284158
Drug: Gallopamil 50
Normalized name: gallopamil 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gallopamil 50 mg t.i.d. (days 8-14)
Study: 6531964
Drug: Suckling mouse
Normalized name: house mouse skin extract
DrugBank: Mus musculus skin (DB10412)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Suckling mouse brain vaccine (SMBV)
Study: 6531964
Drug: Fetal bovine
Normalized name: Fetal Bovine Serum
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fetal bovine kidney vaccine (FBKV) administered subcutaneously
Study: 6531964
Drug: Fetal bovine
Normalized name: Fetal Bovine Serum
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fetal bovine kidney vaccine (FBKV) administered intramuscularly
Study: 30095354
Drug: Botulinum toxin
Normalized name: Botulinum toxin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Botulinum toxin A (BoNT-A) injection plus rehabilitation therapy
Study: 26963844
Drug: Gabapentin (3600
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gabapentin (3600 mg daily)
Study: 23084383
Drug: Early treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Early treatment for retinopathy of prematurity (ROP)
Study: 17438101
Drug: Interferon-alpha2b therapy
Normalized name: Fibroblast interferon
DrugBank: Human interferon beta (DB14999)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Interferon-alpha2b therapy
Study: 11451596
Drug: 0.2 mg/kg/day
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.2 mg/kg/day rhGH during hospitalization